ERBB2 and breast carcinoma: We obtained blood from unselected primary breast cancer patients, patients on follow-up following primary breast cancer treatment, metastatic cases and women with benign breast disease and healthy female controls and analysed cfDNA for the presence of amplified HER2 DNA.